Clinical and metabolic effects of oral contraceptives
Vázquez Hernández, L.; Téllez Martínez, J.; Hicks Gómez, J.J.
Ginecologia y Obstetricia de Mexico 68: 64-69
2000
ISSN/ISBN: 0300-9041 PMID: 10774107 Document Number: 449943
The oral contraception most employed, consists in a combination of estrogen and progestin, the main action in the prevention of ovulation through the inhibition of the secretion of luteinizing hormone (LH) and follicle stimulating hormone (FSH). The progestin in combination with estrogen produces an endometrium not receptive to the oocyte implantation and changes tubal, this affects capacitation and acrosomal reaction. Since 1960s up to date the reports made had been established that the OC had been developed adverse effects such as increase concentration of HDL, increase of apolipoprotein B-100, insulin resistance, increase in SHBG, atherogenicity, alteration in the coagulation factors and increase in the risk of venous thromboembolic disease. This work was elaborated with literature search on MEDLINE between 1985 to 1998, with the purpose to search the collateral effects of Oral Contraceptives evaluated by other authors.